Literature DB >> 36091850

The Omicron Variant of the Sars-Cov-2 Virus As the Dominant Agent of a New Risk of Disease amid the COVID-19 Pandemic.

G G Onishchenko1, T E Sizikova2, V N Lebedev2, S V Borisevich2.   

Abstract

Over the two years that have passed since the WHO announced on March 11, 2020, a pandemic of the new coronavirus disease COVID-19, more than 460 million cases of the disease have been detected in the world, of which more than five million have been fatal. During the natural evolution of the COVID-19 pathogen, dominant variants emerge that account for most new infections. The WHO constantly monitors coronavirus mutations that potentially pose an epidemiological danger. Currently, the WHO divides modified variants of the SARS-CoV-2 virus into variants of concern (VOC) and variants of interest (VOI). The WHO-designated group of variants of concern includes potentially the most dangerous lines, which are characterized by a complex of new properties. This group also includes the Omicron variant, which has become the dominant agent of the new wave of the COVID-19 pandemic. The aim of this work is to analyze the characteristics of the SARS-CoV-2 Omicron strain, the dominant agent of the new wave of the COVID-19 pandemic. The proposed mechanism of origin of the Omicron variant, its geographical distribution, the features of the disease caused by it, and the distinguishing features from diseases caused by the Delta variant and the original Wuhan strain of the SARS-CoV-2 virus, mutations of the Omicron variant compared to the parent strain of the SARS-CoV-2 virus, the genetic variability of the Omicron variant, and the epidemiological characteristics of the disease it causes are considered. Particular attention is paid to evaluation of the preventive and therapeutic effectiveness of the existing medical means of protection against COVID-19 in relation to the Omicron strain. © Pleiades Publishing, Ltd. 2022, ISSN 1019-3316, Herald of the Russian Academy of Sciences, 2022, Vol. 92, No. 4, pp. 381–391. © Pleiades Publishing, Ltd., 2022.Russian Text
© The Author(s), 2022, published in Vestnik Rossiiskoi Akademii Nauk, 2022, Vol. 92, No. 7, pp. 636–646.

Entities:  

Keywords:  COVID-19; Omicron variant; SARS-CoV-2 virus; epidemiological characteristics of disease; medical protective means; mutations; preventive and curative efficacy; vaccination

Year:  2022        PMID: 36091850      PMCID: PMC9447973          DOI: 10.1134/S1019331622040074

Source DB:  PubMed          Journal:  Her Russ Acad Sci        ISSN: 1019-3316            Impact factor:   0.552


  19 in total

1.  The convalescent sera option for containing COVID-19.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.

Authors:  Matthew McCallum; Nadine Czudnochowski; Laura E Rosen; Samantha K Zepeda; John E Bowen; Alexandra C Walls; Kevin Hauser; Anshu Joshi; Cameron Stewart; Josh R Dillen; Abigail E Powell; Tristan I Croll; Jay Nix; Herbert W Virgin; Davide Corti; Gyorgy Snell; David Veesler
Journal:  Science       Date:  2022-01-25       Impact factor: 63.714

Review 3.  Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review.

Authors:  Daniel P Oran; Eric J Topol
Journal:  Ann Intern Med       Date:  2020-06-03       Impact factor: 25.391

4.  Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles.

Authors:  Akshamal M Gamage; Kai Sen Tan; Wharton O Y Chan; Jing Liu; Chee Wah Tan; Yew Kwang Ong; Mark Thong; Anand K Andiappan; Danielle E Anderson; De Yun Wang; Lin-Fa Wang
Journal:  PLoS Pathog       Date:  2020-12-07       Impact factor: 6.823

5.  SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-12-17       Impact factor: 17.586

Review 6.  Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.

Authors:  Hossam M Ashour; Walid F Elkhatib; Md Masudur Rahman; Hatem A Elshabrawy
Journal:  Pathogens       Date:  2020-03-04

Review 7.  A Review of SARS-CoV-2 and the Ongoing Clinical Trials.

Authors:  Yung-Fang Tu; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Yi-Ying Lin; Yung-Hung Luo; Yi-Tsung Lin; Wei-Yi Lai; De-Ming Yang; Shih-Jie Chou; Yi-Ping Yang; Mong-Lien Wang; Shih-Hwa Chiou
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

Review 8.  The neurological manifestations of COVID-19: a review article.

Authors:  Hamid Reza Niazkar; Behdad Zibaee; Ali Nasimi; Narjes Bahri
Journal:  Neurol Sci       Date:  2020-06-01       Impact factor: 3.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.